Establishment of Definitions and Review Process for Consistent Adjudication of Cause- specific Mortality after Allogeneic Unrelated-donor Hematopoietic.

Slides:



Advertisements
Similar presentations
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,  
Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients  Stephanie Farnia,
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos 
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies  Marcelo C. Pasquini,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation  Brian Kornblit, Christian Enevold, Tao Wang, Stephen Spellman, Mike.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Allogeneic Stem Cell Transplantation in Myelofibrosis
National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants  Robert A. Bray, Carolyn K. Hurley, Naynesh.
Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group.
Genome-Wide Association Study of Cause-Specific Transplant-Related Mortality (TRM) after HLA-Matched Unrelated Donor Allogeneic BMT for Acute Leukemia.
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.
Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review  Rahul Mhaskar,
A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous.
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 
Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children  Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,
J. J. Nietfeld, Marcelo C. Pasquini, Brent R
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
A Comparison of Measured Creatinine Clearance versus Calculated Glomerular Filtration Rate for Assessment of Renal Function before Autologous and Allogeneic.
The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia  Jennifer.
Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation  K. Scott Baker, Stella M. Davies, Navneet S. Majhail,
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex by Alyssa I. Clay-Gilmour, Theresa.
Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype  Marcie Tomblyn,
Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States  Song Yao,
B Cells and Transplantation: An Educational Resource
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report 
Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia  George L. Chen, Hong Liu,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Eric J. Chow, Kenneth Wong, Stephanie J. Lee, Kara L
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pauline Damien, David S. Allan 
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age  Lujia Dong,
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Biology of Blood and Marrow Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Mohamed A. Kharfan-Dabaja, Yasser R. Abou Mourad, Hugo F
Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match  Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,
Blood and Marrow Transplant Handbook
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.
Functional Single Nucleotide Polymorphisms (SNPs) in the Major Histocompatibility Complex (MHC) Class II Region Are Associated with Overall Survival (OS)
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Risk of Exposure to Zika Virus and Impact on Cord Blood Banking and Adult Unrelated Donors in Hematopoietic Cell Transplantation: The Canadian Blood Services.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Jason W. Chien, Lue Ping Zhao, Barry Storer, Paul J
Hematopoietic Stem Cell Transplantation in Australia and New Zealand,  
Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation 
Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies  Mary Eapen, Paul O'Donnell,
In Memoriam: E. Donnall Thomas
Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H
Presentation transcript:

Establishment of Definitions and Review Process for Consistent Adjudication of Cause- specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation  Theresa Hahn, Lara E. Sucheston-Campbell, Leah Preus, Xiaochun Zhu, John A. Hansen, Paul J. Martin, Li Yan, Song Liu, Stephen Spellman, David Tritchler, Alyssa Clay, Kenan Onel, Marcelo Pasquini, Philip L. McCarthy  Biology of Blood and Marrow Transplantation  Volume 21, Issue 9, Pages 1679-1686 (September 2015) DOI: 10.1016/j.bbmt.2015.05.019 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Visual summary of the proportion of causes of death in each category as reported by the transplant center that were reclassified by the consensus panel for both cohorts. Black boxes indicate >15% of deaths in that TRM category were reclassified, dotted boxes indicate ≥5 but <15% of deaths in that TRM category were reclassified, white boxes indicate <5% of deaths in that TRM category were reclassified, and gray boxes indicate the percent agreement of the consensus panel with the transplant center. Biology of Blood and Marrow Transplantation 2015 21, 1679-1686DOI: (10.1016/j.bbmt.2015.05.019) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions